
© 2025 TokenPress
Realtime | Geld | Brief | Zeit |
---|---|---|---|
294,55 | 295,55 | 13:03 | |
294,30 | 295,65 | 13:03 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
10:26 | Amgen-Aktie: Kursrallye oder Trendumkehr? | Die Amgen-Aktie (ISIN: US0311621009) hat in den letzten Wochen eine beeindruckende Aufwärtsbewegung hingelegt. Doch kann sich der Biotech-Titel weiter behaupten, oder droht eine Konsolidierung? Technische... ► Artikel lesen | |
07:12 | Celltrion's STOBOCLO And OSENVELT Biosimilars Get FDA Approval Referencing Amgen's PROLIA And XGEVA | THOUSAND OAKS (dpa-AFX) - Celltrion USA, affiliated to South Korean biopharmaceutical company Celltrion, Inc., announced that the U.S. Food and Drug Administration has approved STOBOCLO (CT-P41... ► Artikel lesen | |
Mo | Sinusitis data from Amgen, AstraZeneca's Tezspire spark 'best-in-disease' talk amid Sanofi, GSK competition | ||
Mo | Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis | ||
Sa | Amgen: Positive Results From Tezspire (tezepelumab-ekko) Phase 3 Waypoint Trial Highlight Rapid, Sustained Effect In Chronic Rhinosinusitis With Nasal Polyps | Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery
Data Published in NEJM and Presented at AAAAI/WAO 2025
THOUSAND OAKS... ► Artikel lesen |